ASG Aurora Spine Corporation

Aurora Spine Receives Australian TGA Clearance for ZIP Ultra(TM) MIS Interspinous Fusion System

CARLSBAD, CALIFORNIA--(Marketwired - Feb 21, 2014) - Aurora Spine Corporation (TSX-VENTURE:ASG) announced today that it has received Australian Therapeutic Goods Administration (TGA) clearance for the ZIP Ultra™ Interspinous Fusion System. Providing surgeons and patients with next generation technology, the ZIP is a minimally invasive (MIS) spinal fixation device for spinal fusion and was developed as an alternative to the pedicle screw systems prevalent in the market.

The ZIP Ultra Interspinous Fusion System is listed on the Australian Register of Therapeutic Goods (ARTG #219670) website. The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health. The TGA is responsible for regulating therapeutic goods, including medicines, medical devices and blood and blood products supplied in Australia.

"The receipt of the Australian Therapeutic Goods Administration (TGA) clearance is a significant step forward in Aurora Spine's expansion into the global Minimally Invasive Spinal Device market," says Brent Johnston, Chief Commercialization Officer of Aurora Spine. "Aurora Spine will continue to strive to bring improved fusion technology to patients and position itself as a leader in spinal technology."

About Aurora Spine

Aurora Spine is an early stage company focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies.

Forward-Looking Statements

This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Information" in Aurora Spine's final prospectus (collectively, "forward-looking information"). Forward-looking information in this news release includes information concerning the proposed marketing and commercialization of Aurora Spine's products in certain global markets. Aurora Spine cautions investors of its securities about important factors that could cause Aurora Spine's actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.

Aurora Spine CorporationTrent NorthcuttPresident and Chief Executive Officer(760) 424-2004Aurora Spine CorporationEric FronkChief Financial Officer(760) 424-2004www.auroraspine.us